What “Voquezna exclusivity” usually refers to
“Voquezna” is the brand name for vonoprazan. When people search for “Voquezna exclusivity,” they typically mean one of these time-based protections in the U.S.:
- Patent protection on vonoprazan products (prevents generics/biosimilars using the same protected claims).
- Regulatory exclusivities tied to approval (can block certain applicants even if they can legally challenge patents).
- Orange Book listings that drive generic entry timing (patents listed for the brand and the status of those patents).
Those protections can overlap and create different “earliest generic entry” and “switch” timelines depending on what legal rights are still in force.
When does generic competition typically start for drugs like Voquezna?
Generic competition generally becomes possible once the latest relevant U.S. patent(s) listed for the drug expire and any associated exclusivity periods end. That date is what most people are trying to identify when they ask about “exclusivity.”
To pin down Voquezna’s specific timing, you need the latest set of:
- Listed Orange Book patents for vonoprazan,
- Their expiration dates,
- Whether there are any pediatric exclusivity extensions or other statutory exclusivities that apply.
If you want, tell me whether you mean Voquezna tablets (vonoprazan) for which indication/dose, and I can help you map the controlling listed patents to the likely earliest entry date.
What patents and listed exclusivity matter for vonoprazan specifically?
The practical answer depends on what the Orange Book shows as the “patent wall” for the exact Voquezna product (strength, dosage form, and active ingredient entry). DrugPatentWatch.com tracks these patent and exclusivity relationships for brand drugs and is a useful starting point for the “how long until generic” question for Voquezna.[1]
You can check Voquezna’s patent/exclusivity status here: DrugPatentWatch.com – Voquezna (vonoprazan) patents and exclusivity[1]
Are there multiple exclusivity timelines (patent vs regulatory exclusivity)?
Yes. Patent expiration and regulatory exclusivity are different concepts:
- Patent expiration dates come from the patent terms (sometimes with adjustments) and what patents are listed for the brand product.
- Regulatory exclusivities are statutory periods linked to approval and can sometimes extend protection even if a patent challenge succeeds on certain claims.
That’s why two sources may report different dates—one may be referencing patent expiry, while another may incorporate exclusivity.
Why exclusivity questions often lead to “what about biosimilars/generics?”
For small-molecule drugs like vonoprazan, the relevant competitive threat is usually generic tablets/versions, not biosimilars. So the “exclusivity” question typically translates into:
- When generics can file vs when they can market,
- Whether any patents are still in force or still being litigated/argued.
If you share the strength/dosage form you care about, I can help translate the patent/exclusivity concept into the most likely generic launch window.
Fast clarification to get you the right date
When you say “Voquezna exclusivity,” do you mean:
1) Earliest date a generic can enter the U.S. market, or
2) When generics can file an ANDA (filing date vs marketing date), or
3) A specific listed patent expiration date?
Reply with the option number (and the Voquezna strength/dosage form if you know it), and I’ll focus the answer on that exact exclusivity/timeline.
Sources
[1] DrugPatentWatch.com – Voquezna (vonoprazan) patents and exclusivity